Literature DB >> 19399878

Hyperbaric oxygen therapy protects the liver from apoptosis caused by ischemia-reperfusion injury in rats.

José C Chaves1, Djalma J Fagundes, Manuel De J Simões, Paulo R Bertoletto, Celina T F Oshima, Murched O Taha, Ricardo S Simões, Anna L N Fagundes.   

Abstract

PURPOSE: : The present paper aimed to investigate the role of hyperbaric oxygen treatment (HBO) and the apoptosis in rat liver ischemia-reperfusion injury (IRI).
METHODS: : Thirty-seven male Wistar rats were subjected to 30 minutes of hepatic ischemia and 30 minutes of reperfusion and randomly distributed into six groups: G-I/R (n = 8), control without HBO; G-HBO/I (n = 8), HBO only during the ischemia period; G-HBO/R (n = 8), HBO only during the reperfusion period; G-HBO-I/R (n = 8), HBO during both the ischemia and reperfusion periods; G-Sh (n = 3), HBO without ischemia or reperfusion as sham group; G-C (n = 2) for control of current apoptosis expression on the normal liver tissue. HBO was carried out using a transparent, cylindrical acrylic chamber with a pressure of 2.0 ATA. Hepatic samples were stained for caspase-3 cleavage.
RESULTS: : Apoptotic cells were identified in all groups. In the hepatic specimens of animals HBO-treated during ischemia (GHBO-I), there was a significant decrease (P < 0.001) in the number of cells undergoing apoptosis (1.62 +/- 0.91). The apoptotic index showed no significant difference in the animals HBO-treated during ischemia/reperfusion (5.75 +/- 1.28) compared with the G-I/R (3.5 +/- 0.75), which had no HBO treatment. The apoptosis index (11.25 +/- 1.90) was significantly higher (P < 0.01) in HBO-treated animals during the reperfusion period when compared with any of the other groups.
CONCLUSION: : A favorable effect was obtained when hyperbaric oxygen was administered early during ischemia. The hyperbaric oxygen in later periods of reperfusion was associated with a more severe apoptosis index. (c) 2009 Wiley-Liss, Inc. Microsurgery 2009.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19399878     DOI: 10.1002/micr.20664

Source DB:  PubMed          Journal:  Microsurgery        ISSN: 0738-1085            Impact factor:   2.425


  7 in total

Review 1.  Ischaemia-reperfusion injury and hyperbaric oxygen pathways: a review of cellular mechanisms.

Authors:  Ashish Francis; Richard Baynosa
Journal:  Diving Hyperb Med       Date:  2017-06       Impact factor: 0.887

2.  Hyperbaric oxygen preconditioning attenuates hyperglycemia enhanced hemorrhagic transformation after transient MCAO in rats.

Authors:  Yoshiteru Soejima; Robert P Ostrowski; Anatol Manaenko; Mutsumi Fujii; Jiping Tang; John H Zhang
Journal:  Med Gas Res       Date:  2012-04-11

Review 3.  Hyperbaric oxygen as an adjunctive therapy in treatment of malignancies, including brain tumours.

Authors:  Katarzyna Stępień; Robert P Ostrowski; Ewa Matyja
Journal:  Med Oncol       Date:  2016-08-02       Impact factor: 3.064

Review 4.  Application of hyperbaric oxygen in liver transplantation.

Authors:  Hu Lv; Cui-Hong Han; Xue-Jun Sun; Wen-Wu Liu
Journal:  Med Gas Res       Date:  2016-12-30

5.  Heat Shock Protein 70 (HSP70) Reduces Hepatic Inflammatory and Oxidative Damage in a Rat Model of Liver Ischemia/Reperfusion Injury with Hyperbaric Oxygen Preconditioning.

Authors:  Hsing-Hsien Wu; Chien-Cheng Huang; Ching-Ping Chang; Mao-Tsun Lin; Ko-Chi Niu; Yu-Feng Tian
Journal:  Med Sci Monit       Date:  2018-11-12

6.  Successful treatment of hepatic gas gangrene by open drainage: A case report and review of the Japanese literature.

Authors:  Ryohei Ono; Hiroyuki Kashiwagi; Jun Kawachi; Naoko Isogai; Katsunori Miyake; Takaaki Murata; Rai Shimoyama; Ryuta Fukai; Hidemitsu Ogino; Nobuaki Shinozaki
Journal:  Int J Surg Case Rep       Date:  2018-06-30

Review 7.  Hyperbaric Oxygen Therapy in Liver Diseases.

Authors:  Yun Sun; Yankai Wen; Chanjuan Shen; Yuanrun Zhu; Wendong You; Yuanyuan Meng; Lijuan Chen; Yiping Feng; Xiaofeng Yang; Zuo-Bing Chen
Journal:  Int J Med Sci       Date:  2018-05-22       Impact factor: 3.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.